Arietta et al. showed that phosphorylated ERK1/2 (p-ERK1/2) proteins are predictors of response in recurrent glioblastoma patients to PD-1 inhibition even in absence of BRAF and PTPN11 expression [37]. This evidence concerns the gene BRAF and glioblastoma.